Literature DB >> 25127973

High-sensitivity cardiac troponin for risk prediction in patients with and without coronary heart disease.

Willibald Hochholzer1, Christian M Valina2, Christian Stratz2, Michael Amann2, Daniel Schlittenhardt2, Heinz Joachim Büttner2, Dietmar Trenk2, Franz-Josef Neumann2.   

Abstract

BACKGROUND: In stable patients with unknown coronary anatomy, higher levels of cardiac troponin are associated with an increased risk of cardiovascular events. It was supposed that this association might be explained by the ability of cardiac troponin to detect minor myocardial necrosis which might be caused by subclinical coronary atherosclerosis. Thus, this analysis tested if the predictive value of high-sensitivity troponin T (hsTnT) in stable patients is dependent of the presence or absence of angiographically documented coronary heart disease.
METHODS: Stable patients undergoing elective coronary angiography were enrolled (n=2046). HsTnT was determined before diagnostic procedures. The patients were followed for up to seven years. Primary endpoint was all-cause mortality or non-fatal myocardial infarction. All endpoints were adjudicated by independent physicians. Results were adjusted to a clinical model including independent clinical predictors of the primary endpoint.
RESULTS: Out of the 2046 patients enrolled, 1236 (60%) had a diagnosis of obstructive coronary heart disease. HsTnT predicted independently the primary endpoint (adjusted HR 1.33, 95%-CI 1.21-1.46, P<0.001). The use of hsTnT in addition to the clinical model significantly improved discrimination (c-statistic: 0.751 to 0.773, P<0.001) as well as reclassification of the primary endpoint (NRI=0.362, P<0.001). This significant improvement persisted across various subsets and was independent of the presence of clinically detectable coronary heart disease and other variables.
CONCLUSION: The use of hsTnT in addition to clinical variables significantly improves discrimination and reclassification of patients with respect to all-cause mortality or non-fatal myocardial infarction irrespective of the presence of clinically detectable coronary heart disease. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (Identifier: NCT00457236).
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Coronary heart disease; Mortality; Prognosis; Risk prediction; Troponin

Mesh:

Substances:

Year:  2014        PMID: 25127973     DOI: 10.1016/j.ijcard.2014.07.094

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

1.  Associations between Skeletal Muscle and Myocardium in Aging: A Syndrome of "Cardio-Sarcopenia"?

Authors:  Bryan M H Keng; Fei Gao; Louis L Y Teo; Wee Shiong Lim; Ru San Tan; Wen Ruan; See Hooi Ewe; Woon-Puay Koh; Angela S Koh
Journal:  J Am Geriatr Soc       Date:  2019-08-16       Impact factor: 5.562

2.  Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease.

Authors:  Menglu Liang; John William McEvoy; Yuan Chen; A Richey Sharrett; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2016-08-01       Impact factor: 19.112

3.  Troponin elevation predicts critical care needs and in-hospital mortality after thrombolysis in white but not black stroke patients.

Authors:  Roland Faigle; Elisabeth B Marsh; Rafael H Llinas; Victor C Urrutia; Rebecca F Gottesman
Journal:  J Crit Care       Date:  2015-12-02       Impact factor: 3.425

4.  Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction.

Authors:  Yejin Mok; Yingying Sang; Shoshana H Ballew; Ron C Hoogeveen; Christie M Ballantyne; Wayne Rosamond; Josef Coresh; Elizabeth Selvin; Kunihiro Matsushita
Journal:  Am Heart J       Date:  2019-07-13       Impact factor: 4.749

Review 5.  Novel Risk Stratification Assays for Acute Coronary Syndrome.

Authors:  Haitham M Ahmed; Stanley L Hazen
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

6.  Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study.

Authors:  Anandita Agarwala; Salim Virani; David Couper; Lloyd Chambless; Eric Boerwinkle; Brad C Astor; Ron C Hoogeveen; Joe Coresh; A Richey Sharrett; Aaron R Folsom; Tom Mosley; Christie M Ballantyne; Vijay Nambi
Journal:  Atherosclerosis       Date:  2016-08-25       Impact factor: 5.162

Review 7.  Anthracycline Chemotherapy and Cardiotoxicity.

Authors:  John V McGowan; Robin Chung; Angshuman Maulik; Izabela Piotrowska; J Malcolm Walker; Derek M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  2017-02       Impact factor: 3.727

8.  Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial.

Authors:  Robin Chung; Angshuman Maulik; Ashraf Hamarneh; Daniel Hochhauser; Derek J Hausenloy; J Malcolm Walker; Derek M Yellon
Journal:  Clin Cardiol       Date:  2016-01-25       Impact factor: 2.882

Review 9.  Troponin assay use in the emergency department for management of patients with potential acute coronary syndrome: current use and future directions.

Authors:  William R Fox; Deborah B Diercks
Journal:  Clin Exp Emerg Med       Date:  2016-03-31

10.  Risk prediction in stable cardiovascular disease using a high-sensitivity cardiac troponin T single biomarker strategy compared to the ESC-SCORE.

Authors:  Moritz Biener; Evangelos Giannitsis; Manuel Kuhner; Thomas Zelniker; Matthias Mueller-Hennessen; Mehrshad Vafaie; Kiril M Stoyanov; Franz-Josef Neumann; Hugo A Katus; Willibald Hochholzer; Christian Marc Valina
Journal:  Open Heart       Date:  2018-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.